Key Takeaways
- EmGenisys closed an oversubscribed $1.5 million seed funding round led by Grit Road Partners
- Investors include Tall Grass Ventures and Ag Venture Alliance
- Funding will support commercialization of EmVision, an AI platform for real-time embryo evaluation
- EmGenisys holds 15 U.S. patents and has received awards in both biotech and agtech sectors
- Company aims to expand into other livestock species and launch new reproductive technologies
EmGenisys Raises Seed Capital to Scale AI Platform for Embryo Health Assessment
EmGenisys, an animal health technology company specializing in real-time AI analysis of embryo viability, announced the close of a $1.5 million seed financing round, which was oversubscribed and led by Grit Road Partners. Additional investors include Tall Grass Ventures and Ag Venture Alliance, reflecting strong interest in EmGenisys’ approach to improving embryo transfer outcomes in beef and dairy cattle.
The funding will enable EmGenisys to accelerate the commercialization of its core technology and support expansion into additional livestock species. The company will also focus on developing new tools for improving reproductive efficiency and genetic progress.
AI Meets Embryology: The EmVision Platform
EmGenisys’ flagship product, EmVision, is a machine learning-based software that analyzes 30-second smartphone videos of embryos recorded through a microscope. The platform assesses embryo quality frame-by-frame and generates a real-time health score to guide selection decisions for in vitro fertilization (IVF) and embryo transfer.
Designed for use by veterinarians, embryologists, and producers, the web-based system provides a non-invasive, objective evaluation that aims to improve pregnancy rates and maximize return on genetic investment.
Leadership and Investor Confidence in EmGenisys’ Mission
Founded in 2020 by Dr. Cara Wells and Dr. Russell Killingsworth, EmGenisys has rapidly built credibility through 15 issued U.S. patents, successful pilot deployments, and recognition in both the agtech and biotech sectors. The company was recently awarded the BioTools Innovator Award and the Animal Health Corridor Innovation Award.
“This funding will allow us to advance our AI platform, expand access to our technology, and deliver real impact for beef and dairy producers around the world,” said Dr. Cara Wells, CEO of EmGenisys.
Co-founder Dr. Russell Killingsworth, a veterinary specialist with over four decades of experience in bovine embryo transfer, added, “This financial backing will allow us to continue to develop and improve services that benefit both novice and experienced embryologists and their clients.”
AgTech Investors Signal Strong Support for Reproductive Innovation
Investor partners underscored EmGenisys’ potential to transform livestock reproduction with data-driven tools.
“EmGenisys is advancing a very exciting innovation in the livestock sector,” said Wilson Acton, Managing Partner at Tall Grass Ventures. “Their team has blended artificial intelligence with advanced livestock reproduction technologies in a way others haven’t.”
Mike Jung, Managing Partner at Grit Road Partners, added, “This partnership perfectly aligns with our mission to back cutting-edge AgTech solutions that deliver real, measurable impact for Midwest agriculture.”
Next Steps: Commercialization, Expansion, and New Offerings For EmGenisys
With the seed funding secured, EmGenisys plans to scale up its operations, expand EmVision’s applicability to other livestock species, and launch new product offerings that align with the reproductive and genetic goals of livestock producers.
Headquartered in Driftwood, Texas, EmGenisys continues to position itself as a key player at the intersection of artificial intelligence and animal health, with a mission to bring precision and efficiency to the livestock breeding process.
EmGenisys
EmGenisys, Inc. focuses on improving livestock reproduction through technology. The company’s primary product is a software-as-a-service (SaaS) platform that provides noninvasive analysis of embryo morphokinetics to enhance pregnancy outcomes in assisted reproductive techniques.
